Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
242.8 CHF | +2.77% | +6.59% | -0.72% |
05:14pm | Roche: efficacy of Evrysdi in spinal muscular atrophy | CF |
05:12pm | Roche's Five-year Data Confirms Efficacy, Safety of Evrysdi Drug for Spinal Muscular Atrophy in Children | MT |
Sales 2024 * | 60.39B 67.33B | Sales 2025 * | 63.83B 71.17B | Capitalization | 196B 219B |
---|---|---|---|---|---|
Net income 2024 * | 13.27B 14.79B | Net income 2025 * | 14.76B 16.46B | EV / Sales 2024 * | 3.48 x |
Net Debt 2024 * | 13.77B 15.35B | Net Debt 2025 * | 7.88B 8.79B | EV / Sales 2025 * | 3.2 x |
P/E ratio 2024 * |
14.3
x | P/E ratio 2025 * |
12.9
x | Employees | 103,605 |
Yield 2024 * |
4.04% | Yield 2025 * |
4.15% | Free-Float | 88.91% |
Latest transcript on Roche Holding AG
1 day | +2.65% | ||
1 week | +6.59% | ||
Current month | +5.09% | ||
1 month | +10.84% | ||
3 months | +2.89% | ||
6 months | -2.68% | ||
Current year | -0.72% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 49 | 02-12-31 | |
Severin Schwan
CHM | Chairman | 57 | 07-12-31 |
Alan Hippe
DFI | Director of Finance/CFO | 57 | 11-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bernard Poussot
BRD | Director/Board Member | 72 | 15-03-02 |
Director/Board Member | 59 | - | |
Director/Board Member | 66 | 95-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-07 | 242.8 | +2.77% | 1 410 |
24-06-06 | 238.1 | +0.79% | 30,127 |
24-06-05 | 236.2 | +0.66% | 78,134 |
24-06-04 | 234.7 | +1.12% | 248,605 |
24-06-03 | 232.1 | +0.48% | 377,309 |
Delayed Quote London S.E., June 07, 2024 at 11:20 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+45.82% | 754B | |
+40.95% | 630B | |
-6.16% | 352B | |
+19.86% | 331B | |
+9.32% | 298B | |
+18.45% | 250B | |
+11.88% | 217B | |
+5.90% | 164B | |
-0.73% | 163B |
- Stock Market
- Equities
- ROG Stock
- 0QOK Stock